The report provides a detailed analysis essential for establishing a Zuranolone production plant. It encompasses all critical aspects necessary for Zuranolone production, including the cost of Zuranolone production, Zuranolone plant cost, Zuranolone production costs, and the overall Zuranolone production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Zuranolone production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Zuranolone is an oral neuroactive steroid that is approved by the FDA as the first oral treatment for postpartum depression (PPD) in adults. It is administered as 50 mg once daily in the evening with fat-containing food for 14 days (or 30 mg for severe hepatic/renal impairment). It provides rapid symptom relief starting day 3 and sustained effects up to 4 weeks post-treatment when used alone or with antidepressants. It manages PPD's hormonal and neurochemical disruptions by improving inhibitory neurotransmission, outperforming a placebo. It is also utilised in major depressive disorder, bipolar depression, insomnia, essential tremor, and Parkinson's disease. Its common side effects include sleepiness or drowsiness, dizziness, diarrhoea, fatigue or lack of energy, urinary tract infection, common cold symptoms, and headache.
The market for Zuranolone is driven by its usage in the first oral therapy for postpartum depression (PPD). Its approval by the FDA to treat new mothers of PPD with rapid symptom relief contributes to its market growth. The rising PPD cases, awareness, and maternal mental health investments expand their applications. The industrial Zuranolone procurement is affected by limited API suppliers (with USDMF, GMP, and CEPs) and high speciality pharmacy distribution via partnerships. Also, stable pricing because of favourable cost-effectiveness, short 14-day course logistics, and post-marketing safety monitoring impact its sourcing strategies. Therapy and pre-authorisation requirements favouring cheaper SSRIs and generics, NICE and EC appraisal outcomes for EU reimbursement, and competition from low-cost alternatives affect its market dynamics.
Raw Material for Zuranolone Production
According to the Zuranolone production plant project report, the key raw materials used in the production of Zuranolone include 4-androstene-3,17-dione and Solvents.
Production Process of Zuranolone
The extensive Zuranolone production cost report consists of the following major industrial production process:
- From 4-Androstene-3,17-Dione: The production process of Zuranolone starts with 4-androstene-3,17-dione. It starts with catalytic hydrogenation using Pd/C in HBr/THF to obtain a saturated androstanedione intermediate. A stereoselective 3β-methyl introduction is then achieved using methylaluminium bis(2,6-di-tert-butyl-4-methylphenoxide) (MAD) in combination with methylmagnesium bromide to get a pregnane diketone. After that, Wittig olefination installs a side-chain double bond, which is converted to the corresponding aldehyde through hydroboration–oxidation followed by oxidation. This is followed by bromination and alkylation with appropriate heterocyclic nucleophiles to get Zuranolone as the final product.
Zuranolone is a white to off-white, non-hygroscopic crystalline solid. It has a molecular formula of C25H35N3O2 and a molecular weight of 409.57 g/mol. It has a logP value of 3.93-4.5, making it lipophilic. Its pKa value for acidic is 15.17-17.85 and basic value of 1.36. It has a water solubility of 0.0159 mg/mL and a density of 1.32 g/cm³. It has a boiling point of 574.3 degree Celsius and a topological polar surface area of 78.91 Ų. It has 1 hydrogen bond donor, 4 acceptors, 3 rotatable bonds, and 5 rings. It is highly plasma protein-bound (>99.5%), with extensive CYP3A4 metabolism (no major circulating metabolites >10%).